|
Category & domain (n=)*
|
Statistical significance**
|
|---|
|
P < 0.10
|
P < 0.05
|
P < 0.01
|
Total
|
Not significant
|
|---|
|
Outcome
|
|
Protection duration (n = 6)
|
0
|
3
|
5
|
8
|
1
|
|
Vaccine effectiveness (n = 8)
|
0
|
5
|
9
|
14
|
1
|
|
Vaccine risk (n = 7)
|
0
|
4
|
11
|
15
|
0
|
|
Process
|
|
Dosing & visits (n = 3)
|
1
|
1
|
3
|
5
|
1
|
|
Time (n = 2)
|
0
|
0
|
0
|
0
|
2
|
|
Vaccination age (n = 2)
|
0
|
1
|
2
|
2
|
1
|
|
Vaccine accessibility (n = 1)
|
0
|
1
|
0
|
1
|
0
|
|
Cost
|
|
Cost (n = 5)
|
0
|
1
|
8
|
9
|
0
|
|
Other
|
|
Context (n = 1)
|
0
|
2
|
0
|
2
|
0
|
|
Disease risk (n = 2)
|
0
|
1
|
2
|
3
|
0
|
|
Information (n = 2)
|
1
|
1
|
3
|
5
|
0
|
|
Other disease related factors (n = 1)
|
0
|
0
|
0
|
0
|
2
|
|
Vaccine advice/support (n = 2)
|
1
|
0
|
4
|
5
|
0
|
- *n = number of studies reporting domains. All nine studies reported statistical significance; ** Information is based on main models and pooled data when available (if not, data of separate models/classes wasused). Some studies included more than one attribute related to a particular domain. Totals could hence exceed the total number of studies incorporated.
